Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation.

Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, Ebbesen LH, Rosenberg CA, Hokland P, Ludvigsen M, Stidsholt Roug A.

Blood Adv. 2020 Mar 10;4(5):885-892. doi: 10.1182/bloodadvances.2019001157.

2.

AML - a signature disease in haematology.

Hokland P.

Br J Haematol. 2020 Jan;188(1):7. doi: 10.1111/bjh.16365. Epub 2019 Dec 10. No abstract available.

PMID:
31823364
3.

The concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target.

Hokland P, Woll PS, Hansen MC, Bill M.

Br J Haematol. 2019 Oct;187(2):144-156. doi: 10.1111/bjh.16104. Epub 2019 Aug 2. Review.

PMID:
31372979
4.

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.

Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, d'Altri T, Vitting-Seerup K, Rapin N, Gentil C, Jendholm J, Theilgaard-Mönch K, Reckzeh K, Bullinger L, Döhner K, Hokland P, Fitzgibbon J, Porse BT.

Sci Adv. 2019 Jul 10;5(7):eaaw4304. doi: 10.1126/sciadv.aaw4304. eCollection 2019 Jul.

5.

High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach.

Mollerup S, Asplund M, Friis-Nielsen J, Kjartansdóttir KR, Fridholm H, Hansen TA, Herrera JAR, Barnes CJ, Jensen RH, Richter SR, Nielsen IB, Pietroni C, Alquezar-Planas DE, Rey-Iglesia A, Olsen PVS, Rajpert-De Meyts E, Groth-Pedersen L, von Buchwald C, Jensen DH, Gniadecki R, Høgdall E, Langhoff JL, Pete I, Vereczkey I, Baranyai Z, Dybkaer K, Johnsen HE, Steiniche T, Hokland P, Rosenberg J, Baandrup U, Sicheritz-Pontén T, Willerslev E, Brunak S, Lund O, Mourier T, Vinner L, Izarzugaza JMG, Nielsen LP, Hansen AJ.

J Infect Dis. 2019 Sep 13;220(8):1312-1324. doi: 10.1093/infdis/jiz318.

6.

Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.

Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L.

Br J Haematol. 2019 Mar;184(5):769-781. doi: 10.1111/bjh.15711. Epub 2018 Dec 5.

PMID:
30520015
7.

The Nobel Prize for Medicine awarded for cancer therapy by inhibition of negative immune regulation.

Hokland P, Hokland M, Cotter F.

Br J Haematol. 2018 Dec;183(5):698-700. doi: 10.1111/bjh.15694. No abstract available.

PMID:
30488426
8.

Systematic evaluation of signal-to-noise ratio in variant detection from single cell genome multiple displacement amplification and exome sequencing.

Simonsen AT, Hansen MC, Kjeldsen E, Møller PL, Hindkjær JJ, Hokland P, Aggerholm A.

BMC Genomics. 2018 Sep 17;19(1):681. doi: 10.1186/s12864-018-5063-5.

9.

Acute myeloid/T-lymphoblastic leukaemia (ATML) - a disease entity to look out for.

Hokland P, Hansen MC.

Br J Haematol. 2019 Apr;185(1):178. doi: 10.1111/bjh.15429. Epub 2018 Jul 5. No abstract available.

PMID:
29974929
10.

Complete donor chimerism following 0/10 HLA-mismatched unrelated donor allogeneic hematopoietic stem cell transplantation.

Sørensen CD, Møller BK, Olesen G, Hokland P, Hokland M.

Bone Marrow Transplant. 2018 Dec;53(12):1578-1582. doi: 10.1038/s41409-018-0229-y. Epub 2018 Jun 8. No abstract available.

PMID:
29884849
11.

Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.

Bill M, B van Kooten Niekerk P, S Woll P, Laine Herborg L, Stidsholt Roug A, Hokland P, Nederby L.

J Cell Mol Med. 2018 Apr;22(4):2311-2318. doi: 10.1111/jcmm.13519. Epub 2018 Feb 7.

12.

Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia.

Svenningsen M, Herborg LL, Hokland P, Ludvigsen M.

Dan Med J. 2017 Dec;64(12). pii: A5431.

PMID:
29206098
13.

Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy.

Hansen MC, Nederby L, Kjeldsen E, Petersen MA, Ommen HB, Hokland P.

Leuk Res Rep. 2017 Nov 15;9:1-4. doi: 10.1016/j.lrr.2017.11.002. eCollection 2018. No abstract available.

14.

A clearer light on the role of NK cells in haematological malignancies.

Hokland P, Hokland M.

Br J Haematol. 2017 Nov;179(3):359-360. doi: 10.1111/bjh.14867. Epub 2017 Aug 2. No abstract available.

PMID:
28771658
15.

Differential expression levels and methylation status of ROBO1 in mantle cell lymphoma and chronic lymphocytic leukaemia.

Appe AJ, Aggerholm A, Hansen MC, Ebbesen LH, Hokland P, Bentzen HHN, Nyvold CG.

Int J Lab Hematol. 2017 Jun;39(3):e70-e73. doi: 10.1111/ijlh.12615. Epub 2016 Dec 22. No abstract available.

PMID:
28004534
16.

Cord-Blood Transplantation in Patients with Minimal Residual Disease.

Hourigan CS, Haferlach T, Hokland P.

N Engl J Med. 2016 Dec 1;375(22):2204. doi: 10.1056/NEJMc1612872. No abstract available.

PMID:
27959750
17.

Combination of RNA- and exome sequencing: Increasing specificity for identification of somatic point mutations and indels in acute leukaemia.

Hansen MC, Herborg LL, Hansen M, Roug AS, Hokland P.

Leuk Res. 2016 Dec;51:27-31. doi: 10.1016/j.leukres.2016.10.009. Epub 2016 Oct 21.

PMID:
27821287
18.

Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.

Toft-Petersen M, Nederby L, Kjeldsen E, Kerndrup GB, Brown GD, Hokland P, Stidsholt Roug A.

Br J Haematol. 2016 Nov;175(3):393-401. doi: 10.1111/bjh.14270. Epub 2016 Sep 9.

19.

Can exome scans be expected to be part of real-time decision-making in patients with haematological cancers?

Hokland P, Cotter FE, Hansen MC.

Br J Haematol. 2016 Aug;174(3):486-92. doi: 10.1111/bjh.14183. Epub 2016 Jun 28.

PMID:
27351467
20.

Honest reporting and elucidation of very serious adverse events: a lesson to us all.

Hokland P, Cotter F.

Br J Haematol. 2016 Aug;174(3):341-2. doi: 10.1111/bjh.14159. Epub 2016 Jun 24. No abstract available.

PMID:
27340811
21.

Cholinergic activation enhances retinoic acid-induced differentiation in the human NB-4 acute promyelocytic leukemia cell line.

Chotirat S, Suriyo T, Hokland M, Hokland P, Satayavivad J, Auewarakul CU.

Blood Cells Mol Dis. 2016 Jul;59:77-84. doi: 10.1016/j.bcmd.2016.04.009. Epub 2016 Apr 20.

PMID:
27282572
22.

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

Kämpjärvi K, Kim NH, Keskitalo S, Clark AD, von Nandelstadh P, Turunen M, Heikkinen T, Park MJ, Mäkinen N, Kivinummi K, Lintula S, Hotakainen K, Nevanlinna H, Hokland P, Böhling T, Bützow R, Böhm J, Mecklin JP, Järvinen H, Kontro M, Visakorpi T, Taipale J, Varjosalo M, Boyer TG, Vahteristo P.

Prostate. 2016 Jan;76(1):22-31. doi: 10.1002/pros.23092. Epub 2015 Sep 18.

PMID:
26383637
23.

Novel scripts for improved annotation and selection of variants from whole exome sequencing in cancer research.

Hansen MC, Nederby L, Roug A, Villesen P, Kjeldsen E, Nyvold CG, Hokland P.

MethodsX. 2015 Mar 12;2:145-53. doi: 10.1016/j.mex.2015.03.003. eCollection 2015.

24.

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Hokland P, Ommen HB, Mulé MP, Hourigan CS.

Semin Hematol. 2015 Jul;52(3):184-92. doi: 10.1053/j.seminhematol.2015.04.001. Epub 2015 Apr 7. Review.

25.

Real world data on acute myeloid leukaemia therapy from the developing world--an eye-opener.

Hokland P, Cotter F.

Br J Haematol. 2015 Jul;170(1):1-2. doi: 10.1111/bjh.13410. Epub 2015 Apr 8. No abstract available.

PMID:
25855402
26.

Nature and nurture: a case of transcending haematological pre-malignancies in a pair of monozygotic twins adding possible clues on the pathogenesis of B-cell proliferations.

Hansen MC, Nyvold CG, Roug AS, Kjeldsen E, Villesen P, Nederby L, Hokland P.

Br J Haematol. 2015 May;169(3):391-400. doi: 10.1111/bjh.13305. Epub 2015 Mar 5.

PMID:
25752595
27.

The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.

Ommen HB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C, Tobal K, Hokland P, Schnittger S.

Eur J Haematol. 2015 Nov;95(5):436-41. doi: 10.1111/ejh.12511. Epub 2015 Mar 13.

PMID:
25605311
28.

A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia.

Toft-Petersen M, Kjeldsen E, Nederby L, Grønbæk K, Hokland P, Roug AS.

Leuk Res Rep. 2014 Nov 13;3(2):94-7. doi: 10.1016/j.lrr.2014.09.002. eCollection 2014.

29.

Persistence of DNMT3A mutations at long-term remission in adult patients with AML.

Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, Hokland P, Aggerholm A.

Br J Haematol. 2014 Nov;167(4):478-86. doi: 10.1111/bjh.13062. Epub 2014 Aug 4.

PMID:
25371149
30.

Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.

Roug AS, Hansen MC, Nederby L, Hokland P.

Br J Haematol. 2014 Oct;167(2):162-76. doi: 10.1111/bjh.13048. Epub 2014 Aug 7. Review. Erratum in: Br J Haematol. 2015 Mar;168(6):920.

PMID:
25130287
31.

Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.

van Kooten Niekerk PB, Petersen CC, Nyvold CG, Ommen HB, Roug AS, Nederby L, Hokland P, Kjeldsen E.

Br J Haematol. 2014 Jan;164(1):53-60. doi: 10.1111/bjh.12589.

PMID:
24903628
32.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15. Erratum in: Cancer Cell. 2014 Jun 16;25(6):861. Cancer Cell. 2015 Apr 13;27(4):603-5.

33.

Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.

Sørensen CD, Jørgensen JM, Nederby L, Hokland P, Nyvold CG.

J Immunol Methods. 2014 Apr;406:131-6. doi: 10.1016/j.jim.2014.03.004. Epub 2014 Mar 13.

PMID:
24631717
34.

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene.

Ommen HB, Hokland P, Haferlach T, Abildgaard L, Alpermann T, Haferlach C, Kern W, Schnittger S.

Br J Haematol. 2014 Jun;165(5):618-28. doi: 10.1111/bjh.12792. Epub 2014 Feb 24.

PMID:
24611505
35.

Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms.

Jeyaratnam DC, Baduin BS, Hansen MC, Hansen M, Jørgensen JM, Aggerholm A, Ommen HB, Hokland P, Nyvold CG.

Exp Hematol. 2014 Jun;42(6):448-56.e4. doi: 10.1016/j.exphem.2014.02.005. Epub 2014 Mar 4.

PMID:
24607956
36.

Janet Rowley 1925-2013: a rock star of haematology and genetics.

Hokland P.

Br J Haematol. 2014 May;165(3):269-70. doi: 10.1111/bjh.12808. Epub 2014 Mar 3. No abstract available.

PMID:
24588512
37.

Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab.

Mogensen TH, Bernth-Jensen JM, Petersen CC, Petersen MS, Nyvold C, Gadegaard KH, Hokland M, Hokland P, Larsen CS.

BMC Hematol. 2013 Apr 11;13(1):4. doi: 10.1186/2052-1839-13-4.

38.

Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.

Roug AS, Hokland LB, Segel E, Nielsen K, Toft-Petersen M, Van Kooten Niekerk PB, Hokland P, Nederby L.

Cytotherapy. 2014 Mar;16(3):392-401. doi: 10.1016/j.jcyt.2013.11.006. Epub 2014 Jan 11.

PMID:
24424268
39.

Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm.

Herborg LL, Nederby L, Kjeldsen E, Grønbæk K, Hokland P, Hansen M, Celik Hansen M, Roug AS.

Leuk Res Rep. 2013 Jul 4;2(2):51-3. doi: 10.1016/j.lrr.2013.06.001. eCollection 2013.

40.

hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.

Roug AS, Larsen HØ, Nederby L, Just T, Brown G, Nyvold CG, Ommen HB, Hokland P.

Br J Haematol. 2014 Jan;164(2):212-22. doi: 10.1111/bjh.12614. Epub 2013 Oct 24.

PMID:
24152218
41.

Publishing data from failed cytogenetic assays- what can we learn?

Hokland P, Cotter F.

Br J Haematol. 2014 Jan;164(2):163-4. doi: 10.1111/bjh.12623. Epub 2013 Oct 24. No abstract available.

PMID:
24151825
42.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

43.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

44.

Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.

Torgersen ML, Engedal N, Bøe SO, Hokland P, Simonsen A.

Blood. 2013 Oct 3;122(14):2467-76. doi: 10.1182/blood-2013-05-500629. Epub 2013 Aug 22.

PMID:
23970379
45.

Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia.

Silkjaer T, Nyvold CG, Juhl-Christensen C, Hokland P, Nørgaard JM.

Eur J Haematol. 2013 Oct;91(4):295-303. doi: 10.1111/ejh.12166. Epub 2013 Aug 20.

PMID:
23826975
46.

Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.

Hokland P, Cotter F.

Br J Haematol. 2013 Aug;162(4):429-30. doi: 10.1111/bjh.12419. Epub 2013 Jun 15. No abstract available.

PMID:
23772825
47.

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D.

Leukemia. 2013 Oct;27(10):1996-2005. doi: 10.1038/leu.2013.151. Epub 2013 May 14.

48.

Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology.

van Kooten Niekerk PB, Roug AS, Petersen CC, Ommen HB, Kjeldsen E, Bendix K, Nyvold CG, Nederby L, Hokland P.

Br J Haematol. 2013 Jul;162(1):141-4. doi: 10.1111/bjh.12339. Epub 2013 Apr 18. No abstract available.

PMID:
23593974
49.

Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia.

Silkjaer T, Nørgaard JM, Aggerholm A, Ebbesen LH, Kjeldsen E, Hokland P, Nyvold CG.

Eur J Haematol. 2013 May;90(5):385-96. doi: 10.1111/ejh.12090. Epub 2013 Mar 22.

PMID:
23444869
50.

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.

Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari LM, Mehine M, Schrewe H, Nevanlinna H, Levine RL, Hokland P, Böhling T, Mecklin JP, Bützow R, Aaltonen LA, Vahteristo P.

Br J Cancer. 2012 Nov 6;107(10):1761-5. doi: 10.1038/bjc.2012.428. Epub 2012 Sep 20.

Supplemental Content

Loading ...
Support Center